Show simple item record

dc.contributor.authorAndtbacka, RHI
dc.contributor.authorAgarwala, SS
dc.contributor.authorOllila, DW
dc.contributor.authorHallmeyer, S
dc.contributor.authorMilhem, M
dc.contributor.authorAmatruda, T
dc.contributor.authorNemunaitis, JJ
dc.contributor.authorHarrington, KJ
dc.contributor.authorChen, L
dc.contributor.authorShilkrut, M
dc.contributor.authorRoss, M
dc.contributor.authorKaufman, HL
dc.date.accessioned2016-08-26T15:14:52Z
dc.date.issued2016-12
dc.identifier.citationHead & neck, 2016, 38 (12), pp. 1752 - 1758
dc.identifier.issn1043-3074
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/75
dc.identifier.eissn1097-0347
dc.identifier.doi10.1002/hed.24522
dc.description.abstractBackground Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).Methods Retrospective review of OPTiM identified patients with cutaneous head and neck melanoma given talimogene laherparepvec (n = 61) or GM-CSF (n = 26). Outcomes were compared between talimogene laherparepvec and GM-CSF treated patients with cutaneous head and neck melanoma.Results DRR was higher for talimogene laherparepvec-treated patients than for GM-CSF treated patients (36.1% vs 3.8%; p = .001). A total of 29.5% of patients had a complete response with talimogene laherparepvec versus 0% with GM-CSF. Among talimogene laherparepvec-treated patients with a response, the probability of still being in response after 12 months was 73%. Median overall survival (OS) was 25.2 months for GM-CSF and had not been reached with talimogene laherparepvec.Conclusion Treatment with talimogene laherparepvec was associated with improved response and survival compared with GM-CSF in patients with cutaneous head and neck melanoma. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1752-1758, 2016.
dc.formatPrint-Electronic
dc.format.extent1752 - 1758
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectMelanoma
dc.subjectHead and Neck Neoplasms
dc.subjectSkin Neoplasms
dc.subjectNeoplasm Invasiveness
dc.subjectGranulocyte-Macrophage Colony-Stimulating Factor
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectDisease-Free Survival
dc.subjectTreatment Outcome
dc.subjectInjections, Intralesional
dc.subjectMultivariate Analysis
dc.subjectProportional Hazards Models
dc.subjectSurvival Analysis
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectOncolytic Virotherapy
dc.subjectKaplan-Meier Estimate
dc.titleCutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
dc.typeJournal Article
dcterms.dateAccepted2016-05-16
rioxxterms.versionofrecord10.1002/hed.24522
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfHead & neck
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume38en_US
pubs.embargo.termsNot known
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0